OXYBUTYNIN CHLORIDE
Clinical safety rating: safe
Other anticholinergic drugs can have additive effects Can cause blurred vision and urinary retention.
Oxybutynin chloride is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), leading to relaxation of the detrusor muscle and reduction of urinary bladder contractions.
| Metabolism | Extensively metabolized by CYP3A4 (primarily in liver and intestinal wall) to active metabolite N-desethyloxybutynin; also undergoes hydrolysis. |
| Excretion | Primarily hepatic metabolism; <0.1% excreted unchanged in urine. Metabolites (e.g., N-desethyloxybutynin) excreted mainly renally. Fecal elimination <0.02%. |
| Half-life | Terminal elimination half-life: 12–13 hours in plasma; clinical effect may persist longer due to active metabolite (N-desethyloxybutynin, half-life ~12–13 hours). |
| Protein binding | ~91–93% bound to plasma proteins, primarily to alpha-1-acid glycoprotein and albumin. |
| Volume of Distribution | 1.0 L/kg (range 0.8–1.3 L/kg) indicating extensive distribution into tissues. |
| Bioavailability | Oral immediate-release: ~6% (extensive first-pass metabolism). Oral extended-release: approximately 40% relative to immediate-release. Transdermal: approximately 9–12% systemic bioavailability. |
| Onset of Action | Immediate-release oral: 30–60 minutes. Extended-release oral: 3–6 hours. Transdermal: 24–48 hours. |
| Duration of Action | Immediate-release: 6–10 hours. Extended-release: up to 24 hours. Transdermal: approximately 96 hours (4 days) per patch. |
| Molecular Weight | 393.9 |
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (100 mg) applied once daily.
| Dosage form | SYRUP |
| Renal impairment | No specific dose adjustment for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution; no standardized guidelines; consider reducing dose or frequency. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution; no specific dose reduction defined; consider lower starting dose. Child-Pugh Class C: contraindicated. |
| Pediatric use | Children >5 years: immediate-release 5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: not recommended in children. Pediatric dosing based on weight not established. |
| Geriatric use | Start with lower dose (2.5 mg orally 2-3 times daily for immediate-release; 5 mg once daily for extended-release) due to increased anticholinergic sensitivity and risk of cognitive impairment. Titrate slowly. Avoid in frail elderly. |
| 1st trimester | Oxybutynin crosses the placenta. Limited human data; animal studies showed embryotoxicity at high doses. Use only if benefit outweighs risk. |
| 2nd trimester | Same as T1. Avoid especially in first trimester if possible. |
| 3rd trimester | May cause neonatal anticholinergic effects (e.g., tachycardia, ileus) if used near term. Use with caution. |
Clinical note
Other anticholinergic drugs can have additive effects Can cause blurred vision and urinary retention.
| FDA category | Animal |
| Placental transfer | Oxybutynin crosses the placenta as it has a molecular weight of 393.9 Da and is lipophilic. Plasma protein binding is ~91% in mother. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Dry mouth |
| Serious Effects |
Uncontrolled narrow-angle glaucomaMyasthenia gravisSevere ulcerative colitisObstructive uropathyGastrointestinal obstructionHypersensitivity to oxybutynin
| Precautions | Exacerbation of narrow-angle glaucoma, Urinary retention and gastric retention (caution in patients with obstructive uropathy or GI obstructive disorders), Decreased cognitive function (especially in elderly; may increase risk of dementia), Heat prostration (risk of hyperthermia in hot environments due to decreased sweating), Potential for CNS effects (sedation, dizziness, confusion) |
| Food/Dietary | Avoid high-fat meals with immediate-release formulation as they may increase absorption and risk of side effects. Transdermal and extended-release formulations can be taken without regard to meals. Grapefruit has no known interaction. Limit alcohol intake due to additive CNS depressant effects. |
Loading safety data…
| Oxybutynin is excreted into breast milk in small amounts. Monitor infant for anticholinergic effects (drowsiness, irritability, feeding difficulty). Not recommended in nursing mothers of preterm or jaundiced infants due to immature drug clearance. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Pregnancy Category B. No evidence of fetal harm in animal studies; inadequate human studies. Use only if clearly needed. |
| Fetal Monitoring | Monitor for maternal anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision); fetal heart rate monitoring not routinely required. |
| Fertility Effects | No specific human data; animal studies show no impairment of fertility. |
| Clinical Pearls | Oxybutynin is an anticholinergic with direct smooth muscle relaxant effects. Use with caution in elderly due to increased risk of CNS effects (drowsiness, confusion, memory impairment). Consider extended-release or transdermal formulations to reduce anticholinergic burden. Monitor for urinary retention, especially in patients with bladder outlet obstruction. Avoid in uncontrolled narrow-angle glaucoma. Reduce dose in hepatic impairment. May exacerbate symptoms of myasthenia gravis. Taper use to avoid rebound urgency. |
| Patient Advice | Take exactly as prescribed; do not crush or chew extended-release tablets. · May cause dry mouth, constipation, blurred vision, or dizziness. Use sugar-free gum or candy for dry mouth. · Avoid alcohol and CNS depressants as they may increase drowsiness. · Report severe abdominal pain, inability to urinate, or eye pain (signs of acute glaucoma). · Use caution when driving or operating machinery until effects are known. · Transdermal patch: apply to dry, intact skin on hip/abdomen/buttock; rotate sites; avoid exposure to heat (can increase absorption). |